| scholarly article | Q13442814 |
| P50 | author | Peter J Neumann | Q87756484 |
| Peter A. Ubel | Q98066077 | ||
| P2093 | author name string | Chaim M Bell | |
| William K Evans | |||
| Elizabeth L Strevel | |||
| Eric Nadler | |||
| Jennifer A Palmer | |||
| Michael A Kozminski | |||
| Scott R Berry | |||
| P2860 | cites work | Physician awareness of prescription drug costs: a missing element of drug advertising and promotion. | Q44330820 |
| Response rates to mail surveys published in medical journals | Q44618062 | ||
| Cancer drugs offer hope, but at huge expense | Q47612903 | ||
| The unbearable rightness of bedside rationing. Physician duties in a climate of cost containment | Q48795245 | ||
| Managed care and medical technology: implications for cost growth | Q50158300 | ||
| The influence of cost-effectiveness information on physicians' cancer screening recommendations. | Q50715996 | ||
| Out-of-pocket health-care expenditures among older Americans with cancer. | Q50744572 | ||
| On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. | Q53444119 | ||
| Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. | Q53615123 | ||
| Specialty distribution of U.S. physicians--the invisible driver of health care costs | Q70592485 | ||
| Cancer therapy costs influence treatment: a national survey of oncologists | Q82392206 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Physician awareness of drug cost: a systematic review | Q28469310 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments | Q30226892 | ||
| Cancer care, money, and the value of life: whose justice? Which rationality? | Q33268609 | ||
| The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study | Q33307460 | ||
| Physicians' attitudes about prescribing and knowledge of the costs of common medications | Q33920872 | ||
| The price tag on progress--chemotherapy for colorectal cancer | Q34335201 | ||
| How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations | Q34714134 | ||
| Pricing medicines: theory and practice, challenges and opportunities | Q36028241 | ||
| Cost of cancer care: issues and implications | Q36702504 | ||
| Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey | Q36702527 | ||
| Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality | Q41729158 | ||
| Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs | Q42671478 | ||
| Do oncologists believe new cancer drugs offer good value? | Q43494341 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 709-717 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Health Affairs | Q260110 |
| P1476 | title | In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival | |
| P478 | volume | 31 |
| Q37157764 | Cost-effectiveness analysis of papillary thyroid cancer surveillance |
| Q39737036 | Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective |
| Q38717851 | Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective |
| Q47804400 | Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States |
| Q36402852 | Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. |
| Q35583822 | Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study |
| Q38627241 | Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. |
| Q88490174 | Integrating clinical and economic evidence in clinical guidelines: More needed than ever! |
| Q37350131 | Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care |
| Q91599579 | The Cost of Oncology Drugs: A Pharmacy Perspective, Part 2 |
| Q52618970 | The importance of greater speed in drug development for advanced malignancies. |
| Q55385665 | US internists' awareness and use of overtreatment guidelines: a national survey. |
Search more.